Healthcare startup Prolocor announces $5.2m funding from seed round and NIH SBIR grant
Prolocor, a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa on the surface of platelets, announced the closing of an oversubscribed $3.2 million seed round. The round was led by Green Park & Golf Ventures, with participation from Labcorp and a group of angel investors.
Prolocor also announced the receipt of a $2 million Phase II grant from the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH). Funds from this grant will be used to support the analytical validation of platelet expression of FcγRIIa as a precision tool.
Clay Heighten, Managing Partner, GPG Ventures: "We are inspired by the work of Co-Founder and CSO Dr. David Schneider in advancing the understanding of thrombotic risk in coronary artery disease and are excited to participate in moving the technology from the lab to the clinic. Dr. Peter DiBattiste is eminently qualified to coordinate the clinical studies, which are expected to prove the value of the Prolocor test."
There are 50 million people living with chronic coronary artery disease in the U.S., Europe and Japan. Of these, over two million suffer from acute coronary syndrome every year. In each case, the doctor and patient must decide whether to use more powerful therapy to prevent thrombosis — increasing the risk of bleeding - or less-intensive therapy - reducing bleeding risk at the expense of more thrombotic events such as heart attack, stroke and cardiovascular-related death. Prolocor's precision tool will guide treatment decisions, effectively matching the intensity of therapy with the risk of events.
DiBattiste, Co-founder and CEO, Prolocor: "The combined funding from the seed round and the NIH SBIR grant will allow us to make significant progress towards validating FcγRIIa as a precision tool for patients with cardiovascular disease."
With this funding in hand, the company plans to establish a CLIA-certified laboratory and complete an ongoing prospective, observational multicenter non-interventional cohort study in 800 patients who have experienced heart attacks.